Table 4 Efficacy by specific cytogenetic abnormalities (ITT population)

From: Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

 

High risk

 

del(17p)

t(4;14)

 

Kd (n=40)

Vd (n=52)

Kd (n=50)

Vd (n=61)

PFS, median months (95% CI)

7.6 (5.6–11.2)

4.9 (3.9–7.5)

10.1 (6.9–NE)

6.8 (5.6–9.4)

 Hazard ratio (95% CI)

0.73 (0.42–1.27)

0.63 (0.38–1.02)

 One-sided P-value

0.13

0.03

 ORR,a % (95% CI)

62.5 (45.8–77.3)

50.0 (35.8–64.2)

78.0 (64.0–88.5)

65.6 (52.3–77.3)

 Odds ratio (95% CI)

1.67 (0.72–3.86)

1.86 (0.79–4.37)

 One-sided P-value

0.12

0.08

  1. Abbreviations: CI, confidence interval; ITT, intention-to-treat; Kd, carfilzomib and dexamethasone; NE, not estimable; ORR, overall response rate; PFS, progression-free survival; Vd, bortezomib and dexamethasone.
  2. aDetermined by Independent Review Committee according to the International Myeloma Working Group Uniform Response Criteria. Patients evaluated for overall response rate had a best overall response of partial response or better.
Back to article page